Orludodstat (BAY 2402234)

製品コードS8847 バッチS884701

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₂₁H₁₈ClF₅N₄O₄

分子量

520.84

CAS No.

2225819-06-5

Solubility (25°C)*

体外

DMSO

100 mg/mL (191.99 mM)

Ethanol

33 mg/mL (63.35 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Clear solution

5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O

5.0mg/ml

Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Orludodstat (BAY 2402234) is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 1.2 nM.
in vitro	BAY 2402234 induces differentiation and inhibits proliferation in AML cell lines across multiple AML subtypes.^[1]
in vivo	BAY 2402234 shows strong monotherapy efficacy and induces differentiation in AML xenograft models in vivo.^[1]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	MOLM-13, HEL, MV4-11, SKM-1 and THP-1 cell lines
	濃度	0.1nM to 1μM
	反応時間	96 h
	実験の流れ	MOLM-13, HEL, MV4-11, SKM-1 and THP-1 cells were plated in 96-well plates at 20,000 cells per well in their respective growth media and were treated with BAY 2402234 in the presence or absence of 100 μM uridine.
動物実験	動物モデル	Female ICR SCID mice
	投薬量	4 mg/kg
	投与方法	p.o.

参考

[1] Christian S,et al.Leukemia.2019;33(10):2403-2415.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus [ J Med Virol, 2024, 96(1):e29372]	PubMed: 38235544
Disulfiram treatment suppresses antibody-producing reactions by inhibiting macrophage activation and B cell pyrimidine metabolism [ Commun Biol, 2024, 7(1):488]	PubMed: 38649462
Disulfiram treatment suppresses antibody-producing reactions by inhibiting macrophage activation and B cell pyrimidine metabolism [ Commun Biol, 2024, 7(1):488]	PubMed: 38649462
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication [ iScience, 2022, 25(5):104293]	PubMed: 35492218
N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication [ bioRxiv, 2021, 10.1101/2021.06.28.450163]	PubMed: N/A
N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication [ bioRxiv, 2021, 10.1101/2021.06.28.450163]	PubMed: None

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。